Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

ABSTRACT:

Background

Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally.

Objective

To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures.

Methods

A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials.

Results

The subjects with MCI were more memory impaired than the cognitively normal subjects but no

SUBMITTER: Petersen RC 

PROVIDER: S-EPMC2809036 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature